Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1855 results
April 2020
-
Featured News
Novartis ranks #4 in PatientView’s 2019 corporate reputation survey of patient organizations
The Corporate Reputation of Pharma 2019 global report reflects the findings of a survey conducted by PatientView with patient organizations worldwide.
-
Story Discovery
COVID-19: Answering your top questions
Novartis CEO Vas Narasimhan answers questions about COVID-19.
-
Featured News
Novartis completes safety review and initiates update to the Beovu® prescribing information worldwide
-
Featured News
World Chagas Disease Day 2020
Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach. -
Featured News
Novartis COVID-19 Response Fund provides support to healthcare workers and communities
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
-
Statement
Novartis announces first European donation of hydroxychloroquine to Switzerland
-
Press release
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus… -
Ad hoc release
Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to…
March 2020
-
Press release
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified… -
Statement
Novartis announces further steps to protect and support its associates during the COVID-19 Pandemic
-
Story Discovery
Visualizing molecular glues
Molecular glues are a new type of medicine inspired by nature’s matchmakers.
-
Ad hoc release
Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data1 If approved, Cosentyx would…